Analysts Set Nektar Therapeutics (NASDAQ:NKTR) PT at $2.33

Nektar Therapeutics (NASDAQ:NKTR) has been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $2.33.

Separately, BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th.

Nektar Therapeutics Stock Up 3.4 %

Shares of NASDAQ NKTR opened at $1.23 on Thursday. Nektar Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $1.93. The business has a 50 day moving average price of $1.28 and a two-hundred day moving average price of $1.34. The firm has a market cap of $226.42 million, a PE ratio of -1.37 and a beta of 0.61.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). The company had revenue of $23.49 million for the quarter, compared to analyst estimates of $17.24 million. Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. During the same period in the previous year, the business posted ($0.27) EPS. On average, analysts anticipate that Nektar Therapeutics will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On Nektar Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of NKTR. Victory Capital Management Inc. acquired a new stake in shares of Nektar Therapeutics during the 2nd quarter worth approximately $29,000. Values First Advisors Inc. bought a new stake in Nektar Therapeutics in the second quarter valued at $56,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Nektar Therapeutics during the first quarter valued at $63,000. SG Americas Securities LLC grew its position in shares of Nektar Therapeutics by 63.0% during the second quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 28,338 shares during the last quarter. Finally, Candriam S.C.A. acquired a new stake in shares of Nektar Therapeutics in the 2nd quarter worth about $99,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.